tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Rapt Therapeutics (RAPT) to Neutral from Underweight with a $14 price target The firm says the rating balances the “de-risked mechanism and significant potential” of the company’s lead asset RPT904 in food allergy/chronic spontaneous urticaria with the prolonged timelines to data in key indications. Rapt has large market opportunities, but given its prior pipeline setbacks, RPT904 “remains somewhat under-the-radar and may need company sponsored data to increase visibility of the asset,” the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1